Real-time stock price, financial statements, consensus target price, insider trading, and technical analysis for BML Inc. (4694:JPX), powered by AI.
BML Inc. is currently trading at ¥3,625. View real-time AI analysis on Alpha Lenz.
View the latest insider trading data for BML Inc. on Alpha Lenz.
BML Inc.'s P/E ratio is 22.6.
“BML Inc. trades at a P/E of 22.6 (fair value) with modest ROE of 4.9%.”
Ask for details →BML Inc. is a prominent player in the pharmaceutical and biotechnology sector, primarily focused on developing and providing a diverse range of diagnostic solutions. The company's core function is to enhance healthcare through innovative diagnostic methodologies, which include laboratory testing services, clinical diagnostics, and bioanalytical assessments. Notably, BML Inc. plays a crucial role in disease prevention and early diagnosis, significantly impacting health outcomes by facilitating timely and accurate medical decisions. The company is pivotal in the healthcare industry, offering its services to hospitals, clinics, research institutions, and pharmaceutical companies, thereby supporting comprehensive patient care and treatment solutions. With its commitment to advancing medical diagnostics, BML Inc. continues to hold a significant position in enhancing healthcare quality and efficiency across various markets worldwide.
“BML Inc. trades at a P/E of 22.6 (fair value) with modest ROE of 4.9%.”
Ask for details →BML Inc. (ticker: 4694) is a company listed on JPX in the Healthcare sector (Diagnostics & Research). It has approximately 4,558 employees. Market cap is $141.3B.
The current price is 3,625 with a P/E ratio of 22.57x and P/B of 1.09x.
ROE is 4.91% and operating margin is 6.54%. Annual revenue is $143.2B.